Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Clinical trial NCT02477891 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT02477891
- Sponsor
- Janssen Research & Development, LLC
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.